Leadership Overview
Curia has 7 executives leading key functions including strategy, information technology, financial management, human resources, and drug development.
Focused on accelerating pharmaceutical innovation, Curia delivers comprehensive research, development, and manufacturing solutions to global biopharmaceutical partners through a commitment to scientific excellence and operational precision.
Focused on accelerating pharmaceutical innovation, Curia delivers comprehensive research, development, and manufacturing solutions to global biopharmaceutical partners through a commitment to scientific excellence and operational precision.
Leadership Roles at Curia
Philip Macnabb - Chief Executive Officer
Philip Macnabb, the Chief Executive Officer at Curia, directs the overarching strategic vision for the organization. Overseeing the transition from R&D to commercial manufacturing, the Chief Executive Officer ensures alignment across all global service lines. This leadership role involves driving long-term growth by expanding the footprint of the company within the competitive pharmaceutical landscape. By fostering partnerships with biopharmaceutical clients, Philip Macnabb directly impacts the ability of the firm to deliver complex therapeutic solutions. Macnabb prioritizes the integration of advanced manufacturing technologies to maintain high quality standards across international markets. Through consistent focus on operational efficiency and scientific advancement, the Chief Executive Officer secures the market position of the organization. Ultimately, Macnabb guides the executive team toward achieving sustainable performance goals while maintaining a commitment to the core mission of accelerating drug development for patients worldwide.

Gerald Auer - Group Chief Financial Officer
Gerald Auer, the Group Chief Financial Officer at Curia, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial planning and analysis, the Group Chief Financial Officer ensures the stability of the business model across all R&D and manufacturing divisions. This leadership role involves monitoring global market trends to inform investment decisions and resource distribution. By optimizing the cost structure of the company, Gerald Auer directly impacts the profitability and long-term viability of the firm. Auer coordinates with the executive team to align financial performance with strategic growth targets in the biopharmaceutical sector. Through rigorous oversight of financial reporting and risk management, the Group Chief Financial Officer maintains transparency and accountability for stakeholders. Ultimately, Auer secures the financial foundation necessary for the company to continue investing in cutting-edge scientific capabilities and expanding the reach of the organization within the international pharmaceutical industry.
Ronald Aungst - President, Drug Product
Ronald Aungst, the President, Drug Product at Curia, oversees the commercial manufacturing and formulation services for pharmaceutical clients. Managing the production lifecycle, the President, Drug Product ensures that all drug products meet rigorous quality and regulatory standards. This leadership role involves scaling manufacturing capacity to meet the evolving needs of the biopharmaceutical market. By optimizing production workflows, Ronald Aungst directly impacts the reliability and speed of the supply chain for customers. Aungst coordinates with technical teams to ensure the seamless transition of products from development to full-scale commercialization. Through the application of advanced manufacturing techniques, the President, Drug Product drives efficiency and consistency across all production facilities. Ultimately, Aungst maintains the reputation of the company as a trusted partner in the pharmaceutical industry by ensuring that every product delivered adheres to the highest standards of safety and efficacy for patients around the world.
James Grabowski - President, Research & Development
James Grabowski, the President, Research & Development at Curia, directs the scientific strategy and laboratory operations for the organization. Overseeing the discovery and development phases of drug programs, the President, Research & Development ensures that the company remains at the forefront of pharmaceutical innovation. This leadership role involves managing the pipeline of research projects to address the unmet needs of biopharmaceutical clients. By fostering a collaborative environment for scientists, James Grabowski directly impacts the success rate of complex research initiatives. Grabowski coordinates with the commercial manufacturing teams to ensure that research breakthroughs translate effectively into scalable products. Through the implementation of cutting-edge laboratory technologies, the President, Research & Development drives the scientific capabilities of the firm. Ultimately, Grabowski secures the position of the company as a leader in the industry by consistently delivering high-quality research outcomes that advance the development of new therapeutic solutions for global markets.
Prakash Pandian - Chief Information Officer
Prakash Pandian, the Chief Information Officer at Curia, architects the digital infrastructure supporting global research and manufacturing operations. Managing the enterprise data strategy, the Chief Information Officer ensures secure and efficient information flow across all laboratory and production facilities. This leadership role involves implementing advanced analytics to optimize R&D workflows and manufacturing output. By modernizing the technological backbone of the company, Prakash Pandian directly impacts the speed and accuracy of service delivery to pharmaceutical clients. Pandian oversees the deployment of robust cybersecurity frameworks to protect sensitive intellectual property and proprietary research data. Through the alignment of digital initiatives with business objectives, the Chief Information Officer drives innovation in how the organization processes complex scientific information. Ultimately, Pandian maintains the integrity of the digital ecosystem, ensuring that all technical systems support the broader goal of delivering high-quality pharmaceutical products to the global market.

Gregory Kuzma - Senior Vice President, Chief Information Officer
Gregory Kuzma, the Senior Vice President, Chief Information Officer at Curia, drives the implementation of scalable software solutions for internal business processes. Overseeing the integration of enterprise resource planning systems, the Senior Vice President, Chief Information Officer ensures that administrative functions support the high-speed demands of pharmaceutical manufacturing. This leadership role involves streamlining cross-departmental communication through advanced digital platforms. By enhancing the connectivity of internal teams, Gregory Kuzma directly impacts the operational agility of the company. Kuzma manages the lifecycle of critical business applications to ensure maximum uptime and efficiency across all regional offices. Through the application of data-driven insights, the Senior Vice President, Chief Information Officer improves the decision-making capabilities of the leadership team. Ultimately, Kuzma fosters a culture of technological excellence, ensuring that the internal infrastructure remains robust enough to support the complex requirements of the global biopharmaceutical supply chain.
Joseph Sangregorio - Chief Human Resources Officer
Joseph Sangregorio, the Chief Human Resources Officer at Curia, directs the talent acquisition and organizational development strategies for the company. Overseeing the recruitment of specialized scientific and manufacturing personnel, the Chief Human Resources Officer ensures that the workforce possesses the expertise required for complex drug development. This leadership role involves cultivating a high-performance culture that aligns with the mission of the organization. By implementing comprehensive training and retention programs, Joseph Sangregorio directly impacts the ability of the firm to maintain a competitive edge in the pharmaceutical industry. Sangregorio manages the alignment of human capital with the strategic goals of the business, ensuring that teams are structured for maximum efficiency. Through the promotion of professional growth and inclusive workplace practices, the Chief Human Resources Officer supports the long-term success of the company. Ultimately, Sangregorio builds the human infrastructure necessary to sustain innovation and operational excellence across all global sites.
Explore Leadership Teams in Manufacturing
Laboratoires Pierre Fabre is a global pharmaceutical and dermo-cosmetics company that develops and manufactures innovative healthcare solutions. Their product offerings include pharmaceuticals, oncology treatments, and dermo-cosmetic products aimed at improving the quality of life for patients. The company serves a diverse clientele, including healthcare professionals and patients across more than 130 territories. With a strong commitment to ethical practices and a focus on natural healthcare, Laboratoires Pierre Fabre collaborates with various partners to drive advancements in health and beauty.
Company Leadership RE
JL
Daiichi Sankyo is a global healthcare company dedicated to transforming lives through scientific innovation and technology, with a strong focus on oncology. The company develops and commercializes a leading portfolio of antibody drug conjugates (ADCs) and other innovative therapies to address diverse medical needs. Its primary clients include healthcare professionals and patients, as it aims to deliver practice-changing medicines that enhance quality of life. With a commitment to research and development, Daiichi Sankyo strives to advance new standards of care in the healthcare industry.
Company Leadership DM
SK
EM
AY
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is headquartered in South Plainfield, New Jersey.
Company Leadership LB
DM

Founded in 1994 and headquartered in Shanghai, China, Fosun Pharma is a company that focuses on the research and development and manufacturing of pharmaceuticals.
Company Leadership YS
AH
YY